However, aberrations rendering tumour cells intrinsically resistant to TGFβ are reportedly common in B-cell lymphomas, either due to reduced expression of the TGFβ receptor (particularly among EBV-positive neoplasms) (Inman and Allday, 2000), or aberrant downregulation of its downstream targets (Stelling et al., 2018). Here, TGFB1 is linked to neoplasm.